Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids.

Kanve Nagaraj Suvilesh Manjunath Yariswamy Yulia I Nussbaum Mohamed Gadelkarim Murugesan Raju Akhil Srivastava Guangfu Li Wesley C Warren Chi-Ren Shyu Feng Gao Matthew A Ciorba Jonathan B Mitchem Satyanarayana Rachagani Jussuf T Kaifi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

PDTOs are efficient preclinical models recapitulating the tumor characteristics and are suitable for drug testing. AKR1B10 can be targeted by repurposing epalrestat to overcome chemoresistance in NSCLC. Epalrestat has the potential to advance to clinical trials in patients with drug-resistant NSCLC due to favorable toxicity, pharmacological profile, and bioavailability.

Keyphrases

drug resistant
small cell lung cancer
clinical trial
multidrug resistant
acinetobacter baumannii
cancer therapy
advanced non small cell lung cancer
oxidative stress
adverse drug
drug delivery
mesenchymal stem cells
cystic fibrosis
study protocol